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Colistin (Polymyxin E) is one of the few cationic antimicrobial peptides commercialized
in both human and veterinary medicine. For several years now, colistin has been
considered the last line of defense against infections caused by multidrug-resistant
Gram-negative such as Acinetobacter baumannii, Pseudomonas aeruginosa, and
Klebsiella pneumoniae. Colistin has been extensively used orally since the 1960s in
food animals and particularly in swine for the control of Enterobacteriaceae infections.
However, with the recent discovery of plasmid-mediated colistin resistance encoded by
the mcr-1 gene and the higher prevalence of samples harboring this gene in animal
isolates compared to other origins, livestock has been singled out as the principal
reservoir for colistin resistance amplification and spread. Co-localization of the mcr-1
gene and Extended-Spectrum-β-Lactamase genes on a unique plasmid has been
also identified in many isolates from animal origin. The use of colistin in pigs as a
growth promoter and for prophylaxis purposes should be banned, and the implantation
of sustainable measures in pig farms for microbial infection prevention should be
actively encouraged and financed. The scientific research should be encouraged
in swine medicine to generate data helping to reduce the exacerbation of colistin
resistance in pigs and in manure. The establishment of guidelines ensuring a judicious
therapeutic use of colistin in pigs, in countries where this drug is approved, is of
crucial importance. The implementation of a microbiological withdrawal period that
could reduce the potential contamination of consumers with colistin resistant bacteria of
porcine origin should be encouraged. Moreover, the management of colistin resistance
at the human-pig-environment interface requires the urgent use of the One Health
approach for effective control and prevention. This approach needs the collaborative
effort of multiple disciplines and close cooperation between physicians, veterinarians,
and other scientific health and environmental professionals. This review is an update on
the chemistry of colistin, its applications and antibacterial mechanism of action, and on
Enterobacteriaceae resistance to colistin in pigs. We also detail and discuss the One
Health approach and propose guidelines for colistin resistance management.
Keywords: colistin, pig, resistance, E. coli, mcr-1 gene, humans, One Health
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INTRODUCTION
Antibiotics in the polymyxin family include five different
chemical compounds (polymyxins A, B, C, D, and E) (Falagas
et al., 2005; Gallardo-Godoy et al., 2016), of which polymyxin
B and colistin (also called polymyxin E) are the only two
polymyxins used clinically (Landman et al., 2008; Cassir et al.,
2013). For humans, two forms of colistin are commercially
available: colistin methanesulfonate sodium (CMS) for parenteral
use and aerosol therapy; and colistin sulfate (CS) for oral and
topical use (Li et al., 2006; Brink et al., 2014). Colistin is used
in human medicine for the treatment of infections due to
multidrug-resistant (MDR) Gram-negative bacteria (GNB) such
as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella
pneumoniae, and carbapenemase-producing Enterobacteriaceae
(Velkov et al., 2009; Azzopardi et al., 2013) and is used as
a last-resort treatment option against these infections (Falagas
and Rafailidis, 2008; Biswas et al., 2012). Recently, the World
Health Organization (WHO) and several government agencies
such as Health Canada have reclassified colistin in the category
of very high importance in human medicine (WHO, 2011;
Government of Canada, 2014). Colistin’s mechanism of action
is mainly related to its attachment to the lipopolysaccharides
(LPSs) of GNB, leading to membrane-permeability disturbance
and cell death (Falagas and Rafailidis, 2008; Biswas et al.,
2012).
Colistin sulfate is the only form of colistin approved
in pig production in some countries for the control of
Enterobacteriaceae infections, particularly for those caused by
Escherichia coli (Guyonnet et al., 2010; Rhouma et al., 2016a).
Since its introduction on the market in the 60s, colistin was used
in pig production in several countries with different purposes;
therapeutically, prophylactically, and even for growth promotion
(Katsunuma et al., 2007; Rhouma et al., 2016a). Interestingly,
in the late 2000s and after decades of colistin use in swine,
several studies began reporting a significant resistance rate
of Enterobacteriaceae to colistin in pigs (Harada et al., 2005;
Enne et al., 2008; Lu et al., 2010; Rhouma et al., 2016a). The
most common mechanism of colistin resistance in E. coli and
Salmonella involves a modification of the lipid A portion of LPS
through the addition of phosphoethanolamine (PEtN) and/or
a 4-amino-4-deoxy-L-arabinose (L-Ara4N), which reduces its
binding to colistin and leads to bacterial resistance (Bergen
et al., 2012; Olaitan et al., 2014). This chromosomal mechanism
of colistin resistance is the result of the activation of the
two-component systems (TCSs) PhoP/PhoQ and PmrA/PmrB
by specific mutations or environmental stimuli leading to an
overexpression of LPS-modifying genes (Olaitan et al., 2014).
However, several studies have reported the isolation of colistin
resistant E. coli strains in the absence of chromosomally
encoded mechanisms (Olaitan et al., 2015; Quesada et al.,
2015). At the end of 2015, researchers identified a stable
plasmid mediated mcr-1 gene encoded for phosphoethanolamine
transferase conferring resistance to colistin in some GNB isolated
from food animals, raw meat, and humans in several countries
(Liu et al., 2016; Rhouma et al., 2016a). The discovery of this
horizontal mechanism of colistin resistance raised alarm bells
about the impact of colistin use on colistin resistance spread in
animal production, especially in swine. In fact, the link between
pigs and humans in terms of colistin resistant E. coli strain
transfer following direct contact has recently been confirmed
(Olaitan et al., 2015). These findings have led to a serious fear
about the possible loss of colistin effectiveness in the treatment
of MDR-GNB in humans. Hence, it is urgent to establish close
cooperation between physicians, veterinarians, and countries to
ensure judicious use of colistin in both veterinary and human
medicine. The application of the One Health concept could
be a solution for the management of colistin resistance in the
human-pig-environment interface.
This review is an update on colistin chemistry, its appli-
cations and antibacterial mechanism of action, and on
Enterobacteriaceae resistance in pigs. We also detail and
examine the One Health concept to arrive at proposed
guidelines for rational use of colistin in swine and humans
and to find ways to prevent bacterial resistance spread in the
human-pig-environment interface.
Please refer to our recent review for rates of colistin resis-
tance in pigs, the possible link between colistin pharmaco-
kinetic/pharmacodynamic (PK/PD), and colistin use and
Enterobacteriaceae resistance emergence in swine (Rhouma et al.,
2016a).
CHEMICAL STRUCTURE OF COLISTIN
AND ITS ANTIBACTERIAL MECHANISM
OF ACTION
Colistin Chemical Structure
Colistin (polymyxin E) is a polymyxin antibiotic produced by
Paenibacillus polymyxa var colistinus (Tambadou et al., 2015)
consisting of a cyclic heptapeptide ring with three positively
charged amine groups, a tail tripeptide moiety with two positively
charged amine groups, and a hydrophobic acyl chain tail
(Figure 1; Li et al., 2006; Bergen et al., 2012; Azzopardi
et al., 2013; Dijkmans et al., 2015; Rhouma et al., 2015).
Colistin is an amphipathic molecule, with hydrophobicity mainly
attributable to the fatty acyl moiety and hydrophilicity due
to the five L-diaminobutyric acid (L-Dab) amino groups (Li
et al., 2006). The L-Dab molecules are positively charged in
positions 1, 3, 5, 8, and 9 (Figure 1). These amino groups
are responsible for the electrostatically interaction between
colistin and the lipid A portion of LPS molecules of GNB
and play a central role in the bactericidal activity of colistin
(Azzopardi et al., 2013). The polymyxins family includes five
chemically distinct compounds (polymyxins A–E) and only
colistin (polymyxin E) and polymyxin B have been used
in clinical practice (Dijkmans et al., 2015). Polymyxin B
and colistin share a similar primary sequence with the only
difference being one amino acid in position 6 in which D-
phenylalanine in polymyxin B is replaced by D- leucine in
colistin (Figure 1; Li et al., 2006; Velkov et al., 2009; Biswas
et al., 2012; Yoshino et al., 2013; Gallardo-Godoy et al.,
2016).
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FIGURE 1 | Chemical structure of colistin is composed of three parts: (A) hydrophobic acyl tail, (B) linear tripeptide segment (C) hydrophilic, heptapeptide
ring. Arabic numeral indicates the position of amino acids on the structure and the reactive amino groups are encircled. R6: D- phenylalanine in polymyxin B or D-
leucine in polymyxin E (colistin).
Two different forms of colistin are available commercially: CS,
which is administered either orally for bowel decontamination
or topically as a powder for skin infections, and CMS, which
is commonly administered intravenously and used exclusively
in human medicine (Michalopoulos et al., 2011; Bergen et al.,
2012). Both can be delivered by inhalation (Li et al., 2006). CS
is the only active ingredient of the polymyxin family and is
approved in some countries for the control of Enterobacteriaceae
infections in pigs (Official Journal of the European Union,
2010; Rhouma et al., 2016a; Wan et al., 2016) and is used
mostly in monotherapy or sometimes in combination with
other substances. Researchers found at least thirty different
components in commercially available colistin, 13 of which
were separated using the isocratic liquid chromatography (LC)
method (Orwa et al., 2000). The two major components of
colistin are colistin A (polymyxin E1) and colistin B (polymyxin
E2), which differ only in the fatty acid side chain (Orwa
et al., 2000). In fact, colistin A and colistin B are acylated
by (S)-6-methyloctanoic acid and (S)-6-methylheptanoic acid,
respectively (Li et al., 2006). The proportion of these two
major components in commercial products differs between the
different pharmaceutical preparations of colistin available on
the market (Bergen et al., 2012; Brink et al., 2014). This could
be due to the fact that colistin is a natural product produced
by fermentation, so its composition can vary considerably
between manufacturers (Brink et al., 2014). In fact, no pure
colistin A and B reference standards are commercially available
(Dotsikas et al., 2011) and no certificates of analysis that include
chemical characterization are available in veterinary medicine to
adequately establish the purity of the marketed CS formulations
(Rhouma et al., 2016a). CS is a polypeptide antibiotic with a
chemical structure characterized by the presence of multiple
peptide bonds documented to predispose CS to chemical and
enzymatic degradation (Chihara et al., 1973; Rhouma et al.,
2015). In fact, in pig simulated gastric fluid (SGF), CS led to
the formation of degradation products that have a significant
antimicrobial activity compared to non-degraded CS (Rhouma
et al., 2015).
Colistin Antibacterial Mechanism of
Action on Enterobacteriaceae in Pigs
Colistin has a narrow antibacterial spectrum with an effect
limited to GNB; Gram-positive bacteria do not contain LPS in
their cell wall and, as a consequence, are excluded from the
spectrum of activity of polymyxins (Dijkmans et al., 2015).
The initial target of colistin is the LPS component of the outer
membrane (OM) of GNB. The most documented steps of colistin
antibacterial activity are described below (Hancock, 1997; Powers
and Hancock, 2003; Velkov et al., 2009; Biswas et al., 2012; Deris
et al., 2014b; Martis et al., 2014; Nation et al., 2014; Yu et al., 2015).
(1) Colistin initially binds to LPS and specifically to lipid A, a
key component of the LPS, through electrostatic interaction
between positively charged Dab residues of colistin and the
negatively charged phosphate groups of lipid A. Lipid A plays
a crucial role in the control of bacterial permeability (Velkov
et al., 2009).
(2) Colistin competitively displaces divalent cations calcium
(Ca2+) and magnesium (Mg2+) that normally stabilize the
LPS and as a consequence the three-dimensional structure of
the LPS is altered. In fact, colistin has affinities for LPS that
are at least three times higher than those for divalent cations
(Hancock, 1997).
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(3) Colistin causes an expansion of the OM monolayer by the
insertion of its hydrophobic terminal fatty acyl chain or the
D-Leu6 -L-Leu7 segment into the OM.
(4) Colistin leads to a permeabilization of the OM by the
formation of destabilized areas through which colistin will
transit the OM via a self-promoted uptake mechanism
(Hancock and Scott, 2000; Straus and Hancock, 2006).
This mechanism explains how colistin acts in synergy
with conventional antibiotics (Hancock, 1997). In fact,
hydrophilic antibiotics such as rifampicin, vancomycin,
meropenem, β-lactam, tigecycline, and gentamicin can work
synergistically due to this disruption of membrane integrity
by colistin (Bolla et al., 2011).
(5) Colistin destroys the physical integrity of the phospholipid
bilayer of the inner membrane (IM) through membrane
thinning by straddling the interface of hydrophilic head
groups and fatty acyl chains (Velkov et al., 2009).
(6) This leads to IM lysis, leakage of intracellular contents and
cell death.
Colistin also exerts an anti-endotoxin activity because it binds
to the lipid A component of LPS (Falagas et al., 2005; S¸entürk,
2005). In this way, colistin prevents endotoxin’s ability to induce
shock through the release of cytokines such as tumor necrosis
factor-alpha (TNF-α) and IL-8 (S¸entürk, 2005; Baeuerlein et al.,
2009).
It should be stressed here again that colistin’s antibacterial
mechanism of action based on membrane lysis death was
the most documented explanation for the effectiveness of this
antibiotic in the treatment of GNB infections. However, its
ultimate mechanism of action is still unknown (Biswas et al.,
2012; Nation et al., 2014). Other mechanisms of polymyxin
bactericidal activity have been proposed such as a vesicle–
vesicle contact pathway (Cajal et al., 1996; Clausell et al., 2007)
and a hydroxyl radical death pathway (Sampson et al., 2012;
Yu et al., 2015). The vesicle–vesicle contact antimicrobial
mechanism described involves the polymyxin B molecule with a
hydrophobic acyl tail that can enter into and cross the OM and
induce a lipid exchange between leaflets of the IM and OM; this
leads to membrane osmotic instability due to the change in the
phospholipid composition, thereby inducing cell lysis (Clausell
et al., 2007). However, this mechanism of action has not been
studied with colistin. It has been shown that polymyxin B and
colistin exert a rapid antimicrobial activity against the sensitive
and multidrug-resistant isolates of A. baumannii and E. coli
through hydroxyl radical production by the Fenton reaction
(Sampson et al., 2012), leading to the formation of hydroxyl
radicals through the reduction of hydrogen peroxide by ferrous
iron (Fe2+). The production of this reactive oxygen species
(ROS) might lead to oxidative damage in the bacterial DNA,
proteins, and lipids and cause cell death (Sharma et al., 2016).
However, this feature of colistin has not yet been evaluated
in clinical practice. Most recently, it was shown that colistin
was able to inhibit the vital respiratory enzyme NADH-quinone
oxidoreductase in the bacterial IM of GNB (Deris et al., 2014a).
This mechanism was regarded as a secondary mode of action of
polymyxins.
PHARMACOKINETICS AND
PHARMACODYNAMICS (PK AND PD) OF
COLISTIN IN PIGS
Clinical PK and PD Studies of Colistin in
Pigs
Unlike for human medicine, only a few studies have been
conducted in pigs to evaluate the PK of colistin following
oral (Guyonnet et al., 2010; Rhouma et al., 2015, 2016b) or
intramuscular (IM) administration (Lin et al., 2005; Tang et al.,
2009; He et al., 2011; Table 1). These studies were performed
using CS, since this is the only form of colistin approved in swine
medicine, and were conducted in healthy pigs. It is reasonable
to think that the PK can be different in sick animals. The oral
CS PK data in pigs were obtained using either a high-pressure
liquid chromatography (HPLC) assay (Guyonnet et al., 2010)
or a LC coupled with the tandem mass spectrometry (HPLC–
MS/MS) method (Rhouma et al., 2015, 2016b). CS PK data in
pigs after parenteral administration were obtained using mostly
microbiological assays (Lin et al., 2005; Tang et al., 2009; Table 1);
these data should be viewed with caution because of the limited
sensitivity of this method and the descriptions of the experiment
conditions.
After oral CS administration in pigs and despite the use of a
very sensitive analytical method, CS plasma concentrations were
very difficult to quantify in healthy pigs (Guyonnet et al., 2010;
Rhouma et al., 2015). A concurrent oral challenge of pigs with
an ETEC: F4 strain did not increase CS intestinal absorption in
a subclinical induction model of post-weaning diarrhea (PWD)
(Rhouma et al., 2015). However, in pigs with clinical PWD
following an experimental oral challenge with the ETEC: F4
strain, CS plasma concentrations were higher in the challenged
groups compared to the unchallenged one (Rhouma et al.,
2016b). These studies confirm that colistin is poorly absorbed
through pig’s gastrointestinal tract even in infected animals
and corroborates the involvement of oral CS administration in
exacerbating colistin resistance by exerting selection pressure on
pig’s intestinal flora (Rhouma et al., 2016a).
Parenteral CS PK studies in pigs were mainly conducted to
study the safety of IM CS administration. The CS intestinal
concentrations through the biliary system elimination were not
determined following IM administration to assess whether or not
colistin exerts a selective pressure on pig’s intestinal microflora
after its parenteral administration. There is no available data in
the literature concerning the possible renal tubular reabsorption
of CS in pigs as previously demonstrated in rats through a carrier-
mediated process (Ma et al., 2009); if this is the case, it would
justify an extension of the colistin withdrawal period in pigs.
Even though some studies have been able to quantify colistin
in the pig’s systemic circulation following its oral administration
using very sensitive methods (Rhouma et al., 2016b), these
concentrations were very low compared to the Maximum Residue
Limits (MRLs) for this molecule in pigs, which supports the short
withdrawal period of 1–7 days for oral CS in pigs (Official Journal
of the European Union, 2010). In fact, the EMEA Committee for
Medicinal Products for Veterinary Use (CVMP) has established
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TABLE 1 | Colistin sulfate PK data in pigs following its oral or intramuscular administration.
Colistin sulfate route of
administration/pigs health
status
Dose used
(mg/Kg)
Quantification
method/LLOQ
Plasma Cmax (ng/mL)
Intestine Cmax (mg/Kg)
Tmax (h) Reference
Oral/clinical healthy 1.2 HPLC Plasma: NA∗ Plasma: NA Guyonnet et al., 2010
250 ng/mL Intestine: 26.97 Intestine: 2
0.5 µg/g
2.4 HPLC Plasma: NA∗ Plasma: NA
250 ng/mL Intestine: 43.57 Intestine: 1
0.5 µg/g
4.8 HPLC Plasma: NA∗ Plasma: NA
250 ng/mL Intestine: 91.75 Intestine: 1
0.5 µg/g
Oral/clinical healthy 2.4 LC–MS/MS Plasma: NA∗ Plasma: NA Rhouma et al., 2015
20 ng/mL Intestine: NA Intestine: NA
Oral/clinical healthy 2.4 LC–MS/MS Plasma: 10.3 Plasma: 0.5 Rhouma et al., 2016b
1 ng/mL Intestine: NA Intestine: NA
Oral/experimental PWD 2.4 LC–MS/MS Plasma: 122.3 Plasma: 0.5
1 ng/mL Intestine: NA Intestine: NA
Oral/clinical healthy 4.8 LC–MS/MS Plasma: 32.2 Plasma: 0.5
1 ng/mL Intestine: NA Intestine: NA
Oral/experimental PWD 4.8 LC–MS/MS Plasma: 338.3 Plasma: 0.5
1 ng/mL Intestine: NA Intestine: NA
IM/clinical healthy 2.4 HPLC Plasma: 2780 Plasma: 0.5 He et al., 2011
150 ng/mL Intestine: NA Intestine: NA
IM/clinical healthy 2.5 Microbiological assay Plasma: NA Plasma: NA Tang et al., 2009
Intestine: NA Intestine: NA
IM/clinical healthy 2.5 Microbiological assay Plasma: 3730 Plasma: 0.5 Lin et al., 2005
Intestine: NA Intestine: NA
IM/clinical healthy 5 Microbiological assay Plasma: 6400 Plasma: 0.5 Lin et al., 2005
Intestine: NA Intestine: NA
PWD, post-weaning diarrhea; LLOQ, lower limit of quantitation; Cmax, maximum plasma or intestinal colistin concentration; Tmax, time at which the Cmax is observed; NA,
information not available. ∗Concentrations of CS were less than the LLOQ of the method.
the MRLs for colistin in swine: 150, 150, 150, and 200 µg/kg
in muscle, liver, fat, and kidney, respectively (Tang et al., 2009).
However, no study has been performed in pigs to assess CS
degradation product toxicity, and no screening tests are available
in the market to detect these products in pig meat (Rhouma et al.,
2015). It was shown that E. coli experimental infection in pigs
increased CS intestinal absorption (Rhouma et al., 2016b), and
authors have claimed that this information should be taken into
consideration when determining the CS withdrawal period in
pigs. Even with intestinal infection, CS systemic concentrations
in pigs remain below MRLs, thus adjusting the withdrawal period
after E. coli infection in pigs should be considered for antibiotics
that are characterized by high oral bioavailability.
The potential for the emergence of E. coli resistance in pigs
during therapy with CS has been shown following its use at the
recommended regimen (100,000 IU/kg/day), as demonstrated
previously (Rhouma et al., 2016b). In this study, despite a rapid
initial reduction in E. coli fecal excretion following CS oral
treatment, the emergence of CS resistance among commensal
E. coli was observed starting from the 3rd day of treatment.
The selection pressure for CS resistant isolates disappeared
after 6 days of CS treatment, and CS resistant E. coli strains
were isolated 6 days after the last treatment (Rhouma et al.,
2016b). This is of significant importance in food safety and
public health perspective because this means pigs that are
treated with CS and given a 1 day withdrawal period as
recommended (Official Journal of the European Union, 2010)
are shipped to slaughter with potential colistin resistant E. coli
in their gut. Therefore, applying a microbiological withdrawal
time for CS resistant bacteria in addition to the chemical
one is of crucial importance to reduce the risk of passage of
these bacteria in pig slaughterhouses to humans through the
handling of raw meat or the consumption of undercooked
meat.
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In order to monitor E. coli colistin resistance in pigs
subsequent to the therapeutic use of this antibiotic in the
treatment of PWD, our team used MacConkey agar medium
supplemented with CS at 2 µg/mL, which represents the
breakpoint value (Rhouma et al., 2016b). We confirmed that this
medium overestimated the number of CS resistant E. coli and
that the isolation of putative resistant bacteria on this medium
requires confirmation by MIC determination using a Mueller–
Hinton broth medium. To overcome this problem related to
the absence of a selective medium for the screening of colistin
resistant bacteria, Nordmann et al. (2016) developed a screening
medium that is able to detect intrinsic and acquired polymyxin-
resistant bacteria without the need to confirm resistance isolates
by MIC determination. The implementation of this medium will
facilitate the monitoring of colistin Enterobacteriaceae resistance
in food-producing animals.
Perspectives for Colistin (PK/PD) Studies
in Pigs
While great advances in colistin research have occurred in the
last decade in both human and veterinary medicine (Rhouma
et al., 2016a), colistin PK/PD data are very limited in pigs.
To successfully combat the development and dissemination of
bacterial resistance against this antibiotic in swine, we believe
that specific CS clinical PK/PD data are of crucial importance
(Table 2).
Furthermore, the recent discovery of a plasmid mediated
mcr-1 gene encoding for Enterobacteriaceae colistin resistance
in farm animals and in humans (Liu et al., 2016) has prompted
several regulatory agencies such as the European Medicines
Agency (EMA) to re-evaluate colistin in farm animals (European
TABLE 2 | Topics that should be investigated to ensure judicious use of
colistin in pigs.
• Uniform composition and dosing of commercial CS formulations
• Studies to establish specific clinical breakpoints of oral colistin against
Enterobacteriaceae
• Clinical trials in field conditions to define the optimum dosing
strategies, including total daily dose and treatment duration
• Generate more data regarding the PK/PD of colistin in animals with
intestinal diseases
• Clinical trials to evaluate the effectiveness of CS treatment at an early
stage of disease to reduce colistin quantities used on farms
• Studies to evaluate the effectiveness of CS parenteral formulations
and their potential risks on resistance occurrence within intestinal
microflora
• Clinical controlled trials to evaluate the potential risks and benefits of
combining colistin with other antimicrobial agents
• Studies to elucidate mechanisms of the development of co-resistance
to colistin on farms
• Studies to evaluate the efficacy and toxicity of colistin degradation
products
• Studies to determine a microbiological withdrawal period for colistin
resistant bacteria in addition to the chemical withdrawal period
• Studies to evaluate the expression of mcr genes on
Enterobacteriaceae in pigs
Medicines Agency, 2016a). More data on colistin PK/PD will be
essential to ensuring judicious use of colistin in pigs (Table 2).
It should be stressed here again that the CS commercially
available is obtained by a bacterial fermentation process
(Brink et al., 2014; Tambadou et al., 2015). Consequently, its
composition may vary between commercially available CMS
products (He et al., 2013), although no study in veterinary
medicine has verified this variability. In addition, the unit of CS
dosing in pig production is not standardized; some practitioners
use international units whereas others use milligrams per kg
of body weight (Ungemach et al., 2006; Guyonnet et al., 2010;
Trauﬄer et al., 2014; Rhouma et al., 2016a). We believe that the
standardization of CS composition and dosage in pigs worldwide
is critical to ensuring judicious use of this antibiotic, and it would
allow comparison between studies in terms of therapeutic efficacy
and resistance rate.
Only one study has determined the CS concentrations in
clinical healthy intestinal tracts of pigs after a single oral
administration of this molecule (Guyonnet et al., 2010). In
this study, colistin concentrations were not detectable in fecal
samples, from the duodenum to ileum, after 4 h of its oral
administration regardless of doses used (25,000, 50,000, or
100,000 IU/kg) (Guyonnet et al., 2010). However, CS is usually
administrated in swine medicine to treat sick animals at a
dose of 50,000 IU/kg body weight every 12 h for 3–5 days
(Official Journal of the European Union, 2010), and the intestinal
Cmax concentrations of colistin were not determined after a
repetitive CS oral treatment to justify the efficacy of this
therapeutic regimen in the treatment of pig’s diseases associated
with Enterobacteriaceae. The duration of CS oral treatment
in pig farms is far longer than 3–5 days as recommended
on product monographs (Chauvin et al., 2002; Van Rennings
et al., 2015). Nevertheless, no study in field conditions has
evaluated the impact of CS treatment duration on its clinical
efficacy in pigs and on bacterial resistance emergence. Our
team showed in experimental conditions that 3 days of CS
oral treatment of pigs challenged with an ETEC: F4 strain was
enough to treat clinical symptoms of PWD in pigs (Rhouma
et al., 2016b), and a positive correlation was observed between
CS treatment duration and CS selection pressure on commensal
E. coli.
It has previously been demonstrated that antimicrobial
activity is related to inoculum size and stage of infection.
Specifically, researchers found that antimicrobial activity may be
higher for a lower bacterial inoculum, and treating experimental
animals at an early stage of infection reduced both the
required dose of antimicrobials and the amplification risk
of bacterial resistance in the intestine (Ferran et al., 2011;
Vasseur et al., 2014). The impact of the inoculum on the
bactericidal activity of colistin has been investigated in vitro
for some strains of P. aeruginosa of human origin (Bulitta
et al., 2010). In this study, killing of the susceptible population
was 23-fold slower for the 109 CFU and sixfold slower for
the 108 CFU than for the 106 CFU. These findings require
further investigation in pigs to study the efficiency of an
early use of CS in the treatment of infections associated with
Enterobacteriaceae in swine and to examine the impact of
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such practice on the resistance amplification risk among pig’s
intestinal bacteria and on colistin amounts used at the farm
level.
Numerous in vitro and in vivo studies using colistin and
various other antibiotics have provided evidence for increased
bacterial killing and decreased emergence of resistance with the
use of certain colistin combinations against MDR Gram-negative
bacteria (Li et al., 2006; Bergen et al., 2012). Using colistin with
other antimicrobial agents (aztreonam, piperacillin, ceftazidime,
imipenem, ampicillin-sulbactam, ciprofloxacin, carbapenems,
and rifampicin) is the most used combination treatment in
human medicine (Li et al., 2006; Martis et al., 2014). Nevertheless,
optimal combinations are not defined, and the relative value of
a combination may vary between bacterial strains (Clancy et al.,
2013).
In swine, and despite the use of some combinations of
colistin with other antimicrobial agents (Table 3), no study has
demonstrated the effectiveness of such association and its role in
colistin Enterobacteriaceae resistance occurrence.
Several susceptibility testing methods are used in pigs to
determine colistin MIC against bacterial strains of porcine origin
(Rhouma et al., 2016a), without specific clinical breakpoints for
colistin against Enterobacteriaceae after its oral use in swine
medicine (Boyen et al., 2010; Richez and Burch, 2016). Such
information is of crucial importance for identifying the colistin
PD index that is predictive of microbiological efficacy and
outcome and to establish the quantitative relationship between
PK and PD parameters (Papich, 2014).
Recently, the plasmid-mediated colistin resistance gene mcr-1
was detected in some Extended-Spectrum-β-Lactamase (ESBL,
blaCTX−M) producing E. coli isolates from pigs in Germany and in
Vietnam (Falgenhauer et al., 2016; Malhotra-Kumar et al., 2016b).
These findings highlight the importance of the active surveillance
of colistin resistance in pigs. The suggested strategies to reduce
colistin use in pigs should never be associated with an increase
in the use of third and fourth generation fluoroquinolones or
cephalosporins or the overall use of antimicrobials on farms as
claimed in the last report of the EMA (European Medicines
Agency, 2016b).
Recommended points of investigation to generate essential
PK/PD data for judicious use of colistin in pig production are
summarized in Table 2.
CLINICAL USE AND INDICATIONS OF
COLISTIN IN PIG PRODUCTION
Indications and Use of Colistin in Pigs
The main indication of colistin in pigs is the treatment of
digestive infections caused by Enterobacteriaceae, especially for
those caused by E. coli (Guyonnet et al., 2010). Colistin is widely
used for the control of PWD in piglets in Europe (Callens et al.,
2012; Kempf et al., 2013). Some epidemiological surveys have
been reported that colistin is sometimes used off-label in pig
farms to treat infections other than intestinal diseases such as
respiratory disease (Chauvin et al., 2002; Catry et al., 2015; Van
Rennings et al., 2015). Approximately 99% of colistin use in pig
production is carried out orally for mass treatment in intensive
husbandry systems (European Medicines Agency, 2016b).
Colistin sulfate is used therapeutically, prophylactically, and
even as a growth promoter in swine in some countries (Rhouma
et al., 2016a). The CS is not approved in pig production in
Canada and in the USA, and this antibiotic is not used as a feed
additive for growth promotion in Europe for at least two decades
(Kempf et al., 2013). However, CS is used in Canada, in some
cases under veterinarian responsibility, as a last resort option for
the treatment of PWD in farms with high rates of resistance to
aminoglycosides (Rhouma et al., 2016b).
However, the most common use of colistin in pig production
worldwide is oral, metaphylactic use (Casal et al., 2007;
Trauﬄer et al., 2014). This practice involves treating all animals
belonging to the same pen – animals with clinical symptoms
as well as clinically healthy ones (Ferran et al., 2011). In its
last report, the EMA recommended using colistin only for
therapy or metaphylaxis purposes in food-producing animals.
All indications for prophylactic use of this molecule should be
prohibited and indications of colistin should be restricted only
for the treatment of enteric infections caused by susceptible
non-invasive E. coli (European Medicines Agency, 2016b).
Colistin is used in pigs at the dose of 100,000 IU per kg of body
weight for three to five consecutive days and divided into two
administrations per day (European Medicines Agency, 2016b).
This therapeutic regimen is recommended for colistin veterinary
formulations administered in drinking water. However, no
recommendation has been made for CS products administered
in feed or by an injectable route in pigs. It is important to stress
the lack of standardization of therapeutic regimen and its impact
on the judicious use of colistin in swine (Catry et al., 2015).
It is difficult to determine the real quantities of colistin used in
pig production worldwide because these data vary considerably
from one country to another, and sometimes colistin amounts
used in pigs in some countries are very high relative to the size of
swine herds (European Medicines Agency, 2016b; Mayor, 2016).
Even within the same country, quantities of colistin in pigs vary
from one survey to another due to the absence of standardized
methods for data collection (Casal et al., 2007; Moreno, 2014).
Combination Therapy
In vitro and clinical investigations examining synergism of
colistin combined with other antimicrobials in human medicine
has been investigated recently and reviewed (Bergen et al.,
2015a,b). The ultimate objective of this combination is to
overcome the suboptimal exposure and the resistance emergence
associated with the use of colistin in monotherapy. Indeed,
the combination of colistin with other antibiotics is intended
to extend the CS spectrum of activity to cover Gram-positive
bacteria and to prevent the emergence of antibiotic resistance
(Zhanel et al., 2006). However, a considerable controversy
regarding the effectiveness of these combinations to counter the
spread of MDR bacteria has been discussed in human medicine
(Tamma et al., 2012). Most recently, Lagerbäck et al. (2016)
showed that colistin and rifampicin combinations were active
in vitro against all NDM-1-producing K. pneumoniae strains
used in their study. However they claimed that such effectiveness
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TABLE 3 | Colistin sulfate combination with other antimicrobial agents used in pig production in France (ANSES, 2016).
Combination∗ Route of
administration
Indications Withdrawal time
(days)
Colistin-Ampicillin IM Septicemia, gastrointestinal, respiratory and genitourinary infections 21
Colistin-Amoxicillin IM Septicemia, gastrointestinal, respiratory infections 10
Colistin-Erythromycin Oral Intestinal infections 21
Colistin-Neomycin Oral Intestinal infections 14
Colistin-Oxytetracycline Oral Intestinal infections 7
Colistin-Spiramycin Oral Intestinal infections 10
Colistin-Trimethoprim Oral Intestinal infections 7
Colistin-Ampicillin-Dexamethasone IM Septicemia, gastrointestinal, respiratory infections 21
∗Colistin is always used as colistin sulfate. IM, intramuscular.
should be further explored in vivo to be considered for clinical
use (Lagerbäck et al., 2016). Parchem et al. (2016) confirmed that
colistin combination therapy should be considered in critically ill
patients with MDR Gram-negative pneumonia.
In swine, CS is typically used in monotherapy for the
oral treatment of infections associated with Enterobacteriaceae
(Rhouma et al., 2016a). However, there are some commercial
formulations where CS is associated with others antimicrobial
agents, mostly with β-lactam antibiotics (He et al., 2011) such as
ampicillin or amoxicillin (Table 3). In fact, it has been shown that
the combination of amoxicillin with colistin has a synergy and
additive affect in vitro against pathogenic E. coli of avian origin,
without antagonism between the two antibiotics (Hamouda
et al., 2011). Colistin combinations were used exclusively for the
curative therapy of pig bacterial infections (Table 3). Moreover,
it has been reported that in the weaning period, colistin was
frequently applied in combination therapy with amoxicillin
against symptoms of arthritis and/or meningitis and PWD in
pigs (Timmerman et al., 2006). Combinations of colistin and
amoxicillin plus zinc oxide (ZnO) in the pre-weaning and
growing stages in feed were also reported in pigs (Moreno,
2014).
Given the lack of appropriately conducted randomized
controlled clinical trials, reliable data on the efficiency of
colistin combination use for the treatment of E. coli in pigs
and its impact on bacterial resistance evolution are very
limited or non-existent. In a recent study, Li H. et al. (2016)
showed that a combination of CS with bacitracin zinc and
chlortetracycline suppressed the increase of tet genes in fecal
samples of weaned pigs. In this study, the relative fecal
abundances of four tet genes (tetX, tetC, tetL, and tetW) were
reduced in pigs treated with a combination of chlortetracycline,
bacitracin zinc, and CS compared with the group treated only
with chlortetracycline (Li H. et al., 2016). However, in this
study no information was reported regarding the evolution of
resistance to colistin following the combination use of these
antibiotics.
With the lack of solid microbiological evidence on the
effectiveness and the impact on bacterial resistance evolution of
colistin combination therapy in pigs, the CVMP recommended
the withdrawal of marketing authorizations for all veterinary
formulations containing colistin in combination with other
antimicrobial substances (European Medicines Agency, 2016b).
Heavy metals such as zinc are widely used in pigs, especially
for the control of PWD in combination with colistin, and is
incorporated into swine feed at levels of 125–3000 mg/kg of feed
(Holman and Chénier, 2015). Zinc oxide fed at pharmacological
levels reduces diarrhea and mortality and improves growth in
pigs (Fairbrother et al., 2005). However, there are two major
concerns regarding the use of ZnO in swine. On the one hand,
there is environmental pollution because of the high levels of
supplementation, and on the other there is co-selection and co-
resistance where antibiotic resistance genes (ARGs) are located
on the same mobile genetic element as ZnO resistance genes
(Holman and Chénier, 2015). To the best of our knowledge, no
study has investigated whether or not resistance genes associated
with colistin and heavy metals could be carried on the same
mobile genetic element. Such information is crucial since ZnO is
among the proposed strategies to reduce colistin quantities used
for the control of PWD in pig production (European Medicines
Agency, 2016b).
In addition to colistin combination therapy used in field
conditions (Table 3), there are other combinations with this
antibiotic that have been used in several scientific studies to
evaluate the efficacy of some colistin alternative substances
(Table 4).
These studies (Table 4) that evaluated the therapeutic efficacy
of colistin combination therapy in pigs were carried out in
China and focused primarily on clinical effectiveness not the
emergence of antimicrobial resistance. Therefore, no information
was available concerning the evolution of colistin bacterial
resistance subsequent to the use of these combination therapies
in swine, and we do not know whether these combinations are
used in practice on pig farms in China.
MECHANISMS OF Enterobacteriaceae
RESISTANCE TO COLISTIN
Owing to an excessive use of colistin in pig production for
many decades, several studies conducted with swine reported the
isolation of E. coli and Salmonella strains with high percentages
of resistance to colistin (Rhouma et al., 2016b). In the present
review we will detail the mechanisms of resistance to colistin for
Salmonella and E. coli, due to the importance of these two bacteria
in both swine and human health.
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TABLE 4 | Colistin combination with other antimicrobial agents in scientific studies conducted in pigs.
Combination Doses in feed
(mg/kg)
Treatment
duration (days)
E. coli (log10 CFU/g
of caecal digesta)
Weight gain (g/d) Reference
Kitasamycin-
Colistin sulfate-
Olaquindox
50-
100-
60
14 N/A 307b Li et al., 2008
Kitasamycin-
Colistin sulfate-
Chlortetracycline
50-
80-
150
35 4.69a 505a Li et al., 2012
Kitasamycin -
Colistin sulfate
100-
800
19 3.09a 367a Wu et al., 2012
Kitasamycin-
Colistin sulfate
100-
40
28 N/A 528a Huang et al., 2015
Enramycin-
Colistin sulfate-
Zinc oxide
200-
200-
2000
28 N/A 787b Kuang et al., 2015
N/A, not available. a: Statistically significant compared to the control group; b: Not statistically significant compared to the control group.
Chromosomal Resistance
An initial and essential step in colistin action on GNB is the
electrostatic interaction between the positively charged peptide
of this antibiotic and the negatively charged lipid A of LPS (Deris
et al., 2014b). Chromosomal resistance to colistin in Salmonella
and E. coli is most often mediated by modifications of LPS,
which result in alterations in the target and reduced binding of
the antimicrobial (Biswas et al., 2012). Changes in LPS consist
in a modification of lipid A with the addition of a 4-amino-
4-deoxy-L-arabinose (L-Ara4N) and/or phosphoethanolamine
(PEtn). These molecules reduce the net negative charge of
LPS and as a consequence increase the resistance to colistin
(Needham and Trent, 2013). In Salmonella and E. coli, the
biosynthesis of l-Ara4N and/or PEtn is mediated by PmrA/PmrB
and PhoP/PhoQ two-component response regulators and sensor
kinase systems (Falagas et al., 2010). In fact, the PhoPQ and
PmrAB TCSs in Salmonella and E. coli have been reviewed
extensively elsewhere (Needham and Trent, 2013; Olaitan et al.,
2014). A brief overview is provided here with a focus on the more
recent discoveries.
PmrB and PhoQ are sensor cytoplasmic membranes activated
respectively by high concentrations of Fe3+ and low pH and by
low concentrations of Mg2+ and Ca2+ or certain antimicrobial
peptides (McPhee et al., 2003; Rubin et al., 2015). In colistin
resistant Salmonella, apart from an environmental stimuli such
as low Mg2+ concentration, a mutation in the PmrA/PmrB
and/or PhoP/PhoQ TCS is the major mechanism involved in
LPS modification (Olaitan et al., 2014). In Salmonella, PhoPQ
further influences lipid A modification by activating the PmrAB
system through the activation of PmrD (Kato et al., 2012).
However, it was proposed in E. coli that the two systems are
not coupled because PmrD does not activate the PmrA/PmrB
system (Winfield and Groisman, 2004). This hypothesis was
initially justified by a high divergence between the Salmonella and
E. coli PmrD proteins (Winfield and Groisman, 2004). However,
it was later found that E. coli PmrB possesses higher phosphatase
activity that exceeds the same activity of the Salmonella homolog,
and the replacement of the E. coli pmrB gene with the Salmonella
homolog was able to render E. coli resistant to polymyxin under
PmrD-inducing conditions with low concentrations of Mg2+
(Chen et al., 2011). Moreover, it has been demonstrated that the
sRNA MgrR of E. coli was also involved in the regulation of lipid
A modification (Moon and Gottesman, 2009). Most recently,
Rubin et al. (2015) have shown that in E. coli, another unknown
bacterial system activates PmrD under low Mg2+ conditions to
promote lipid A modification, even in the absence of PhoPQ.
Mutations in TCS corresponding to E. coli and Salmonella can
cause their constitutive over expression, leading to permanent
modification of lipid A by L-Ara4N and PEtN (Olaitan et al.,
2014). Recently, various mutations have been identified in both
pmrA and pmrB genes of colistin-resistant E. coli isolated from
healthy pigs and pigs with intestinal disease (Table 5). Mutations
in the PmrAB TCS are mostly involved in the development of
resistance to colistin in E. coli (Quesada et al., 2015).
For PmrA, mutations mostly occurred in the phosphate
acceptor domain, while for PmrB, mutations most commonly
occurred in the kinase domain (Quesada et al., 2015).
Of note, regardless of the mutation location in PmrA or PmrB
genes, there was no association with a difference in MIC of these
colistin resistant E. coli strains (Table 5).
Despite the fact that polymorphism in the PmrAB system has
been reported in vitro in Salmonella (Sun et al., 2009), Quesada
et al. (2015) did not detect any of the protein polymorphisms
of PmrA and PmrB sequences in colistin resistant Salmonella
isolates from swine lymph nodes. However, the polymorphism
of genes encoding the PhoPQ system in colistin-resistant
Salmonella has not been investigated in this study. Recently, an
in-depth investigation of these Salmonella isolates showed that
100% of them harbored the plasmid carrying the mcr-1 gene
(Quesada et al., 2016).
Furthermore, the effects of colistin resistance on virulence
and on in vitro and in vivo fitness costs have been extensively
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TABLE 5 | Mutations in two-component systems conferring resistance to colistin in E. coli of pig origin.
Bacteria Health status/samples Gene Mutation in aa MIC (mg/L) Reference
E. coli Clinical healthy/feces pmrA S39I 4 Quesada et al., 2015
R81S
E. coli Clinical healthy/feces pmrB V161G 4 Quesada et al., 2015
E. coli Experimental PWD/feces pmrA G53R 8 Thériault, 2015
E. coli Experimental PWD/feces pmrB T156M 8 Thériault, 2015
aa, amino acid; PWD, post-weaning diarrhea; MIC, minimum inhibitory concentration.
studied in other GNB such as A. baumannii and K. pneumoniae
(Beceiro et al., 2014; Choi and Ko, 2015). A study of the fitness
costs of colistin resistant Salmonella pmrAB mutants in vitro
and in a mouse model showed low fitness costs for these strains
(Sun et al., 2009). Nevertheless, to the best of our knowledge no
study has followed the fitness costs of colistin resistant E. coli
mutants. Many studies have discussed the factors affecting the
fitness cost of colistin resistance, including growth retardation,
impaired virulence, increased susceptibility to other antibiotics,
and substantially reduced clinical invasiveness (López-Rojas
et al., 2011; Pournaras et al., 2014). In swine, it has been reported
that oral colistin treatment is accompanied by a selection pressure
on the colistin resistant E. coli commensal population (Rhouma
et al., 2016b). Further investigations are required to study the
fitness costs of colistin resistant E. coli and Salmonella of porcine
origin.
Plasmid-Encoded Colistin Resistance
Before November 2015, several studies in human and in swine
medicine confirmed the isolation of E. coli isolates confirmed
resistant to colistin without having a mutation in pmrA and/or
pmrB genes (Olaitan et al., 2015; Quesada et al., 2015). The
discovery for the first time in early November 2015 in China
of a plasmid mediated colistin resistance-1 (MCR-1) protein in
Enterobacteriaceae (Liu et al., 2016) has provided explanation
for the other potential colistin resistance mechanisms in GNB.
Initially, this plasmid was considered to be a phenomenon
relegated to China (Paterson and Harris, 2016), however the
mcr-1 gene was soon after isolated in several countries on 4
continents: Asia, Africa, Europe, and the Americas (Rhouma
et al., 2016a; Schwarz and Johnson, 2016; Skov and Monnet,
2016).
Very recently, in June 2016, a novel plasmid-mediated colistin
resistance gene, mcr-2, was identified in colistin resistance E. coli
isolates from porcine and bovine origin in Belgium (Xavier et al.,
2016b). The mcr-2 gene was detected with higher prevalence than
of mcr-1 gene among colistin-resistant E. coli of porcine origin.
MCR-1 and MCR-2 proteins showed 80.65% of identity and
are members of the phosphoethanolamine transferase enzyme
family that promotes the addition of a phosphoethanolamine
group to lipid A, leading to a decreased affinity of colistin for the
LPS (Liu et al., 2016; Xavier et al., 2016b). In Liu et al. (2016)
study, the mcr-1 associated plasmid, designated pHNSHP45, is
approximately 64 Kb in size and is an IncI2-like plasmid that
harbors a predicted 83 open reading frames (ORFs) with a G+C
content of 42.7%. The plasmid pHNSHP45 carrying mcr-1 gene
was initially isolated in July 2013 from an E. coli strain recovered
from a pig farm (Shanghai, China) and showed resistance to
most antibiotic families except the carbapenems (Liu et al.,
2016). Subsequently, mcr-1 has been reported in different plasmid
incompatibility groups from different animal species, including
IncHI2 (200–290 Kb), pVT553 (62 Kb), IncX4 (30 Kb), and
IncP (79 Kb) plasmids in E. coli from broilers poultry, bovine,
and swine origin (Anjum et al., 2016; Falgenhauer et al., 2016;
Malhotra-Kumar et al., 2016a; Perreten et al., 2016; Veldman
et al., 2016) and IncX4 (30 Kb) plasmids in Salmonella from
chicken and turkey meat (Veldman et al., 2016; Webb et al.,
2016). Xavier et al. (2016a) isolated the mcr-1 gene in pKP81-
BE plasmid (91 Kb) from colistin resistant E. coli of porcine
origin. The pKP81-BE plasmid showed a G+C content of 44.9%
and belonged to IncFII incompatibility type with 4% similarity
compared to pHNSHP45. These findings showed that mcr-1 has
horizontally transferred to other plasmid types, leading to an
increase in its target bacterial range (Li A. et al., 2016; Tse and
Yuen, 2016).
The mcr-2 associated plasmid, designated pKP37-BE, is
approximately 35 Kb in size and is an IncX4 incompatibility
type, with a G+C content of 41.3%, and did not carry any other
resistance genes (Xavier et al., 2016b).
The mcr-1 gene has been identified in Enterobacteriaceae
derived from humans, food, farm animals (Liu et al., 2016),
vegetables (Zurfuh et al., 2016), the environment including water
(Petrillo et al., 2016), and even wild migratory bird (Ruzauskas
and Vaskeviciute, 2016). The mcr-1 gene has also been identified
in several multidrug resistant bacteria such as ESBL producing
and carbapenemase-producing E. coli of chicken and swine origin
(Falgenhauer et al., 2016; Yao et al., 2016). In colistin resistant
E. coli, a co-localization of mcr-1 and blaCTX−M genes on a unique
IncHI2-type plasmid was also reported in chickens (Grami et al.,
2016; Sun et al., 2016) and in calves (Haenni et al., 2016). The
co-localization of mcr-1 with an ESBL gene on a conjugative
plasmid increases the possibility of bacterial resistance to colistin
and of broad-spectrum cephalosporins being maintained, even
without the use of theses antibiotics in food animals. This finding
poses significant challenges for successful clinical treatment of
GNB and for resistance control strategies in both veterinary and
human medicine. Veldman et al. (2016) reported for the first
time a chromosomally located mcr-1 gene in two colistin resistant
E. coli isolated from veal calves. In this study, the mcr-1 gene was
associated with the insertion sequence (IS) ISApl1-mcr-1 (or an
mcr-1-containing mobile element) located immediately upstream
of mcr-1, as also reported in plasmid pHNSHP45 (Liu et al.,
2016). ISApl1 is a member of the IS30 family, which was initially
identified in Actinobacillus pleuropneumoniae (Tegetmeyer et al.,
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2008). The presence of this IS in association with the mcr-1
gene strongly suggests that this gene is able to translocate to
the chromosome and to different plasmid backbones – as well
as between bacterial strains. Furthermore, the mcr-2 gene was
associated with an IS of the IS1595 superfamily (Xavier et al.,
2016b).
In swine, to the best of our knowledge, the plasmid-borne
mcr-1 gene has been observed in at least 2 enterobacterial
species, E. coli and Salmonella, in∼12 countries on four different
continents (Rhouma et al., 2016a; Schwarz and Johnson, 2016).
Pig-to-human transmission of MCR-1 colistin resistance has
already been reported (Olaitan et al., 2015, 2016a), raising serious
concerns about the consequences of the use of this antibiotic in
pig productions on human healthcare.
In pigs, the mcr-1 gene was isolated mainly from colistin
resistant E. coli strains with variable prevalence between
countries; China (20.6%), Vietnam (22%), Belgium (13.2%),
Brazil (2%), Spain (0.68%), Germany (0.51%), and France (0.50%)
(Falgenhauer et al., 2016; Fernandes et al., 2016; Liu et al.,
2016; Malhotra-Kumar et al., 2016a; Nguyen et al., 2016; Perrin-
Guyomard et al., 2016; Quesada et al., 2016). Most recently, in
the USA pig production, the mcr-1 gene was identified for the
first time in a colistin resistant E. coli strain isolated from a pig
from South Carolina (Meinersmann et al., 2016). In these studies,
despite using the same technique (PCR) for mcr-1 gene screening,
it is difficult to compare these results between countries because
of the lack of data on previous antibiotic treatments in sampled
pigs, on the quantities of colistin used at the farm level, on
the potential combination of antibiotics with colistin, and on
the health status of the pigs. Moreover, there are no published
longitudinal studies on pigs that quantify the link between
colistin quantities used on farms and the evolution of bacterial
resistance against this antibiotic.
Almost all studies conducted on pigs worldwide to screen
mcr-1 gene presence in enterobacterial species reported that
colistin resistant strains harboring this gene also showed
resistance to one or several classes of antibiotics conventionally
used in swine such as: Aminoglycoside, Sulfonamide,
Trimethoprim, Tetracycline, Quinolone, Lincosamide, β-lactam,
and third generation cephalosporin (Anjum et al., 2016;
Falgenhauer et al., 2016; Malhotra-Kumar et al., 2016b; Nguyen
et al., 2016). This multi-resistance of mcr-1 positive E. coli strains
in pigs was associated with the presence of a sul3-containing class
1 integron, In640, in the plasmid’s mediated mcr-1 gene. This
integron showed the presence of genes encoding resistance to
trimethoprim (dfrA12), aminoglycosides (aadA1a and aadA2),
sulfonamides (sul3), and phenicols (cmlA1) (Xavier et al., 2016a).
Furthermore, IncX4 plasmids have been shown to harbor mcr-1
and mcr-2 genes a swell as ESBL genes (Xavier et al., 2016b).
In the study of Quesada et al. (2016), the mcr-1 gene was
screened and detected in three colistin resistant Salmonella
strains isolated from 122 lymph nodes and in two colistin
resistant E. coli strains isolated from 439 swine fecal samples.
This study was the first in swine to demonstrate the existence
of a plasmid carrying mcr-1 gene, in addition to a mutation
in PmrAB TCS, in two colistin resistant E. coli strains. The
coexistence of these two colistin resistance mechanisms in E. coli
was not associated with a difference in the MIC of these strains
compared to resistant Salmonella strains that expressed only the
plasmid carrying mcr-1 gene (Quesada et al., 2016). It should
be stressed here that the mcr-1 gene found in colistin resistant
enterobacterial strains of porcine origin was often associated with
low levels of resistance; the MICs of 4 or 8 mg/L observed for
most isolates are only 2–4 times higher than the EUCAST clinical
breakpoint (2 mg/L) (Anjum et al., 2016; Liu et al., 2016; Quesada
et al., 2016). Fernandes et al. (2016) reported the isolation of a
colistin-susceptible E. coli strain carrying the mcr-1 gene from
the fecal sample of a healthy pig. This finding, suggests that
mcr-1-positive isolates may be difficult to detect if only the mcr-1
gene is screened in colistin resistant isolates. Further studies are
needed to examine the expression of mcr-1 gene in E. coli and
to determinate the promoter and the operon responsible for this
expression.
ONE HEALTH PERSPECTIVES
Importance of the One Health Concept in
Colistin Resistance Management
Currently, colistin is an antibiotic widely used in veterinary
medicine, particularly in pigs, for the oral treatment of
intestinal infections caused by Enterobacteriaceae (Rhouma
et al., 2016a). In humans, colistin is used for the treatment of
infections caused by MDR-GNB and is considered to be a last-
resort antibiotic treatment option for carbapenemase-producing
Enterobacteriaceae infections (Gurjar, 2015). During the last
decade, research on colistin experienced a significant increase,
especially regarding the mechanism of resistance of colistin and
the optimization of its therapeutic regimen using the PK/PD
relationship (Michalopoulos and Falagas, 2011; Olaitan et al.,
2014).
Recently, the mcr-1 gene was isolated from colistin resistant
E. coli strains from several farm animals: pigs (Rhouma et al.,
2016a), piglets (Malhotra-Kumar et al., 2016a), chickens (Shen
et al., 2016), cattle (Suzuki et al., 2016), and veal calves
(Haenni et al., 2016). A strong similarity was found between the
different classes of plasmid carried mcr-1 genes in these animal
productions, and the successful gene-plasmid combination was
mainly attributed to the presence of ISApl1 upstream in the mcr-1
gene (Falgenhauer et al., 2016). These findings are in favor of a
possible movement of this mobile genetic element between the
various animal productions (Falgenhauer et al., 2016; Figure 2).
In addition to their use in pigs, polymyxins and especially
polymyxin B are used in some countries for the treatment of
coliform and Pseudomonas mastitis in cows (Du Preez, 2000),
and this antibiotic is sometime used for this purpose as an extra-
label drugs in cattle such as in Canada and in the United States
(Smith et al., 2005). Intramammary infusions of 1–2 million units
of polymyxin B/quarter gave an efficiency for the treatment of
cows with severe cases of coliform mastitis (Smith et al., 2005).
Although, some studies have reported the isolation of colistin
resistant E. coli strains harboring the mcr-1 gene from cow with
mastitis (Suzuki et al., 2016), the role of polymyxin B, used for
the treatment of mastitis, in colistin resistance still unknown.
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FIGURE 2 | Circulation of colistin resistant Escherichia coli harboring mcr-1 gene between animals-environment-food and humans.
Furthermore, colistin is used outside of North America orally in
calves and lambs at a dose of 100.000 IU/kg b.w day divided in
two identical doses for three consecutive days for the treatment
of gastrointestinal diseases caused by GNB (Official Journal of
the European Union, 2010). This use could explain the isolation
of bacteria resistant to colistin in calves, even despite the lack of
data on an preliminary treatment of these animals with colistin
(Haenni et al., 2016).
On the other hand, colistin is used in some countries such
as China for the control of intestinal infection caused by GNB
in chicken, turkeys, rabbits and ducks (Dowling, 2013). Colistin
was incorporated into the feed of these animals at the dose
of 3.33 mg/kg b.w for turkeys, 3.8 mg/kg b.w for rabbits and
chickens, and 20 mg/kg for ducks (Zeng et al., 2010). Colistin
was also used in the drinking water in laying hens at the dose
of 3.8 mg/ kg b.w (Goetting et al., 2011). Furthermore, colistin is
widely used in Europe for the oral treatment of E. coli infections
in chicken and laying hens at the dose of 75.000 IU/kg b.w day
for 3–5 consecutive days in the drinking water (Official Journal of
the European Union, 2010; Le Devendec et al., 2015). Although,
several studies have confirmed the isolation of bacteria resistant
to colistin harboring mcr-1 gene from avian origin, however, to
the best of our knowledge no scientific study has investigated the
resistance of GNB to colistin in turkeys, rabbits, and ducks.
In addition, the mcr-1 gene was also isolated from wild
migratory birds such as the European herring gull (Larus
argentatus) in Lithuania (Ruzauskas and Vaskeviciute, 2016) and
the kelp gulls (Larus dominicanus) in Argentina (Liakopoulos
et al., 2016). The role of these migratory birds in the spread of the
mcr-1 gene between continents should not be underestimated.
The mcr-1 gene was identified in resistant E. coli strains
isolated from environmental samples such as river water (Zurfuh
et al., 2016), chicken feed in trough (Yu et al., 2016), and ready-
to-eat vegetables (Zurfuh et al., 2016). Therefore, the role of
animal manure used in the fertilization of agricultural lands in
the environmental dissemination of the mcr-1 gene needs to be
verified. Several studies have reported the isolation of colistin
resistant bacteria from pig manure (Hölzel et al., 2010).
In addition, the mcr-1 gene was identified in resistant E. coli
strains isolated from food samples such as chicken and pork
meat (Liu et al., 2016), ground beef (Mulvey et al., 2016), and
retail meats (chicken, pork, and beef) (Kuo et al., 2016). These
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foods of animal origin represent a major route of contamination
with the mcr-1 gene for slaughterhouse workers and consumers
(Figure 2).
The gene encoding plasmid-mediated colistin resistance, was
also identified in resistant E. coli strains isolated from humans
with gastroenteritis or wound infections (Doumith et al., 2016;
Falgenhauer et al., 2016) and from asymptomatic people (Olaitan
et al., 2016a). The mcr-1 gene was isolated from humans
from four continents, showing that plasmid-mediated colistin
resistance has already spread worldwide.
It was reported that food animals are the main source of
human contamination by the MCR-1 and MCR-2 (Nordmann
and Poirel, 2016; Rhouma et al., 2016a; Xavier et al., 2016b).
However Ruppé et al. (2016) isolated the mcr-1 gene in colistin
resistant E. coli from five children with ages ranging between 2
and 27 months who did not have pets or a history of animal
contact. Moreover, despite the fact that colistin is not approved
in animal production in the USA, McGann et al. (2016) reported
for the first time in the USA, the identification of mcr-1 gene
in a colistin resistant E. coli strain cultured from a woman with
a urinary tract infection (UTI). However this strain remained
susceptible to several other antimicrobial agents (McGann et al.,
2016). These findings suggest that mcr-1 is already widespread in
the environment and transmissible via various routes to humans.
Thereby, there is also a potential risk of the transfer of mcr-1
gene from human to animal. However such transfer should be
investigated in future studies.
Most recently, mcr-1-harboring E. coli was isolated from
healthy dogs and cats in a pet shop in Guangzhou, China (Zhang,
2016). An interesting finding in this study was that the mcr-1
gene in colistin resistant E. coli was isolated from a worker at
this pet shop – and it was the same E. coli strain clonally related
to those originating from dogs. This finding is in favor of a
possible transmission of mcr-1-harboring E. coli between dogs
and humans.
Polymyxins are used in dogs and cats mostly for topical
indications (Mateus et al., 2011; De Briyne et al., 2014). In
fact, polymyxin B is used in the treatment of canine otitis
externa, and it showed synergy with miconazole against E. coli
and P. aeruginosa (Pietschmann et al., 2013). Polymyxin B used
also in ophthalmic suspension for the treatment of keratitis in
dogs (Beckwith-Cohen et al., 2015). For the treatment of this
ophthalmic disease, polymyxin B is commonly associated with
other drugs such as neomycin, and dexamethasone (Beckwith-
Cohen et al., 2015), or chloramphenicol (Hindley et al., 2016).
Furthermore, it was shown that colistin used at the dose of 12.
500 IU/kg IM for 5 days in combination with ampicillin had
demonstrated an anti-endotoxic effects in dogs with naturally
occurring endotoxic shock (S¸entürk, 2005). Despite the isolation
of E. coli resistant to polymyxins harboring the mcr-1 gene from
dogs and cats, it is difficult to determine the role of polymyxin B
administered topically in the exacerbation of colistin resistance in
dog’s or cat’s intestine.
Neither the role of waste and contaminants from the
pharmaceutical industry nor the role of fish farms has been
documented as a source of colistin resistance amplification in the
environment. In fact, it has been reported that administration
of colistin sulfate with other antibiotics in the diets of fish
significantly improved feed conversion and promoted their
growth rate (Hao et al., 2014). To the best of our knowledge, no
study has documented the isolation of colistin resistant E. coli
strains or mcr-1 gene from fish.
Transmission of mcr-1 gene resistance from animals to
humans can take place through a variety of routes (Figure 2).
Therefore, the management of colistin resistance requires global
and coordinated action between the different actors in order
to intercept this resistance spread and preserve the efficacy of
colistin for the treatment of MDR-GNB in human medicine.
We believe that the One Health concept is more important
than ever to better manage the impact of colistin resistance
in human and veterinary medicine. Such a concept needs a
global strategy to develop collaborations and interdisciplinary
communication between concerned specialists (Figure 3).
Action in Swine Medicine
The use of colistin in swine has contributed to the intensification
of modern pig productions by assuring successful weaning,
higher animal densities, and most likely helped to reduce
economic losses caused by E. coli infections such as PWD and
edema disease (Rhouma et al., 2016a). Economic gains have come
at a considerable cost, which is being borne, in particular, by
public health and other stakeholders such as the environment
and the animals themselves. In fact, the recent discovery of a
plasmid-mediated mcr-1 gene encoding for colistin resistance in
Enterobacteriaceae has aroused great concern about the possible
loss of colistin effectiveness for the treatment of MDR- GNB
in humans. Because of the high rate of isolates carrying the
mcr-1 gene isolated from animals compared to humans, livestock
production has been pinpointed as a reservoir of the mcr-1
determinant (Nordmann and Poirel, 2016), hence the need for
rapid action in food animals to prevent the spread of colistin
resistance (Figure 3). This section will focus on interventions in
swine medicine but is applicable to all animal productions where
colistin is used.
The Use of Colistin as a Growth Promoter
This practice should be banned internationally. In addition to
the fact that antimicrobials for growth promotion can generally
be purchased without veterinary involvement, low subinhibitory
concentrations of antibiotics used to improve animal growth has
been shown to promote antibiotic resistance emergence (Aminov
and Mackie, 2007; Andersson and Hughes, 2010; Nosanchuk
et al., 2014). No recent studies have been able to clearly establish
a link between the use of antibiotics as growth promoters and
the improvement of animal performance in modern farming
conditions with a high level of sanitation (Diarra and Malouin,
2014).
The Use of Colistin for Prophylaxis and Metaphylactic
Purposes
This usage is involved in the increase of colistin quantities
used in pigs and increases its presence as waste in the
environment (Rhouma et al., 2016a). Such usage of an antibiotic
of very high importance in human medicine should be
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FIGURE 3 | Schematic representation of various actions to be undertaken to ensure reliable management of colistin resistance in a One Health
perspective. SDD, selective decontamination of the digestive tract; ARG, antibiotic resistance genes.
strictly avoided in swine. Intestinal disease prevention in pigs
should be based mainly on livestock preventive management
measures (optimal temperature, vaccination, sanitation, housing
conditions, applying biosecurity rules, etc.) (Fairbrother et al.,
2005; Aarestrup et al., 2008a).
The Use of Colistin for Therapeutic Purposes
Nevertheless that colistin is a cheap therapeutic strategy with
certain efficacy against Enterobacteria associated disease in swine,
it has been shown that the oral use of colistin for the treatment
of pigs in an experimental PWD model was associated with a
pressure selection on E. coli populations (Rhouma et al., 2016b).
Therefore, the use of colistin as the first therapeutic choice to treat
intestinal infections in pigs should be avoided. The therapeutic
alternative to colistin should not be an antibiotic belonging to
β-lactam family because of the co-localization of mcr-1 and ESBL
genes in the same mobile genetic element. In addition, in its very
recent advice, the EMA required that the reduction of colistin use
in farm animals should not be associated with an increase in the
consumption of fluoroquinolones, third- and fourth-generation
cephalosporins, or the overall use of antimicrobials (European
Medicines Agency, 2016b).
Requirements for Colistin Therapeutic Use
Clinical diagnoses of the disease by veterinarians and the
isolation of pathogen agent linked with the antibiogram tests
to determinate bacterial susceptibility to colistin are essential
to justifying its therapeutic use. Isolation from the animal
husbandry of bacteria harboring the mcr-1 gene should be
considered a strong reason not to use colistin on that farm.
Moreover, the veterinarian should ensure that colistin
prescribed is used in farms only for the treatment of sick
pigs as recommended; compliance with label instructions (no
underdosing or prolongation of dosing interval, withdrawal
period) is of paramount importance. Any deviations from the
guideline recommendations must be justified and recorded. In
this context, extra-label use of colistin in some countries where
this antibiotic is not approved in swine such as in Canada, must
take place within a valid veterinarian-client-patient relationship.
An analysis of the specific situation at farms and a determination
that there are no alternatives to this antibiotic for the treatment
of this case is required. Research is very important in order to
establish a microbiological withdrawal period that could reduce
the risk that pigs sent to slaughter contain colistin resistant
bacteria or mcr genes in their gut.
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Surveillance and Monitoring of Colistin Use on Farms
Veterinarians should ensure that colistin use targets clinical
disease, should consider reduction of its use whenever practical,
and should direct management and husbandry issues at the same
time. Veterinarians should also consider laboratory examination
as a routine practice to evaluate the effectiveness of colistin
treatment and to monitor the sensitivity of infectious strains on
the farm. Educational and awareness campaigns for employers
and pig farmers are essential to generate an understanding
that can support the veterinarian to withhold colistin. The
professional organization of each country should develop
clinical-practice guidelines on the judicious use of colistin. Data
on colistin usage in food animals are critically important because
they provide a basis for the development of national policies
and they guide the risk of colistin resistance management and
assess the effect of possible interventions (Aarestrup et al.,
2008b). At a minimum, these data should include national
use of colistin in kilograms of active ingredient on an annual
basis and data should be stratified by animal species (Merle
et al., 2012). The OIE and WHO recommend collecting the
amount of antibiotics in food animals (WHO, 2004). Finally,
the standardization of a data collection method regarding the
use of colistin in farms between countries is very important to
evaluate the effectiveness of such interventions to manage colistin
resistance spread.
Monitoring of Colistin Resistance
There are many national antimicrobial resistance monitoring and
surveillance programs that already exist and are well-established
in many countries (Gelbrand et al., 2015; Table 6). Among
the principles of the One Health approach is the improved
use of existing natural resources and implementation, which
includes the monitoring of colistin resistance spread in both
human and veterinary medicine. However, regulations and
practices vary widely between these surveillance programs and
are influenced by the economic and social context of each country
(Laxminarayan et al., 2013).
Coordination between the various stakeholders is paramount
for effective surveillance systems at the country level. In
Canada, a new initiative to better manage the dissemination
of antimicrobial resistance at the human-animal interface was
established by the Public Health Agency of Canada in 2015.
The aim of this program, called the Canadian Antimicrobial
Resistance Surveillance System (CARSS), is to strengthen the
coordination and integration of antimicrobial resistance and
antimicrobial use activities and information in Canada and to
consolidate surveillance from seven existing systems (Gelbrand
et al., 2015).
Practical Conditions for the Reduction of Colistin Use
on Farms
Governments should fund research to enhance our
understanding of environmental and genetics factors that
facilitate the development of infectious disease in food
animals, and to examine alternative strategies for the use of
antibiotics on farms. Financial assistance for farmers in the
implementation of sustainable practices and interventions to
prevent infections, such as sanitation, housing, improvement
of nutritional programs, and immunization, is very important
for the reduction of the use of colistin or other antibiotics on
farms. In addition, the preparation of guides and educational
material for veterinarians and farmers on appropriate disease
management and treatment based on the recent results of
research is crucial for the responsible use of antimicrobials in
farms. Efforts to improve microbiological laboratories are vital
to help veterinarians undertake rapid therapeutic action with the
most appropriate antibiotic and at an early stage of the disease
(Årdal et al., 2009). Finally, the competent authorities should
clearly define guidelines for colistin marketing, sales, and use on
farms.
Action in the Environment
In addition to the isolation of colistin resistant bacteria from
manure, water, migratory birds, and vegetables (Hölzel et al.,
2010; Schwarz and Johnson, 2016), the toxicity impact of colistin
on the environment is a topic of concern (Bressan et al.,
2013; Guo et al., 2014). Indeed, it has been shown that the
presence of colistin at therapeutic concentrations in swine farm
wastewater was associated with a toxicity against ammonia-
oxidizing bacteria (AOB) (Bressan et al., 2013). These AOB
are involved in the biodegradation of xenobiotic compounds
and in the conversion of ammonia to nitrites in wastewater
treatment plants (Bressan et al., 2013). The ecotoxicity effect
of colistin was demonstrated in the earthworm Eisenia fetida;
colistin caused significant damage to its intestinal epithelium
and caused the induction of stress-related gene expressions (Guo
et al., 2014).
In addition, it has been reported that colistin-resistant E. coli
were isolated from wild rabbits (Oryctolagus cuniculus) and
wild hares (Lepus europaeus) that have not been previously
treated with colistin (Dotto et al., 2014). Consequently, wildlife
may represent another potential reservoir of colistin resistance
bacteria in the environment that could contaminate humans
through contaminated food and water or by direct human and
animal contact (Gelbrand et al., 2015).
This section will be devoted to the possible interventions to
limit the spread of colistin resistant bacteria and genes in the
environment via pig manure (Figure 3).
Reducing the Use of Antibiotics on Farms
It has been estimated that about 75% of the administered
antibiotics is not absorbed by animals but is excreted via
the feces or urine (Chee-Sanford et al., 2009). This finding
is even more pronounced with colistin, which is very poorly
absorbed in animal’s gastrointestinal tract (Rhouma et al.,
2016a). It has also been reported that the frequency of bacteria
carrying antimicrobial resistance genes is high in pig manure
compared to other farm animals (Heuer et al., 2011), and a
high frequency and concentration of ARGs was detected around
swine farms (Chen et al., 2010). Therefore, the role of pig
manure is not to be underestimated in the dissemination of
colistin resistance in the environment. It is crucial to consider
reducing the use of antibiotics on farms, especially critically
important antimicrobials, in favor of other measures such as
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TABLE 6 | Examples of antimicrobial resistance monitoring and surveillance programs in some countries.
Countries Name of surveillance program Directed by Target
European Union The European Antimicrobial Resistance
Surveillance System (EARSS)
European Centre for Disease Prevention and
Control (ECDC)
Humans
Denmark The Danish Antimicrobial Resistance Monitoring and
Research Program (DANMAP)
Danish Ministry of Food, Agriculture and
Fisheries and the Danish Ministry of Health
Humans, animals,
and food
Canada The Canadian Integrated Program for Antimicrobial
Resistance Surveillance (CIPARS)
Health Canada Humans, animals,
and meat
United States National Antimicrobial Resistance Monitoring System
(NARMS)†
Food and Drug Administration Center for
Veterinary Medicine (FDACVM)
Humans, animals,
and meat
Norway The Norwegian AMR surveillance program (NORM) The Norwegian Ministry of Health and Social
Affairs
Humans, animals
Japan The Japanese Veterinary Antimicrobial Resistance
Monitoring Program (JVARM)
Ministry of Agriculture, Forestry and Fisheries Animals
† In collaboration with the United States Department of Agriculture (USDA) and the Center for Disease Control and Prevention (CDC).
the improvement of nutritional programs, housing, and animal
immunization (Pruden et al., 2013).
Biological Management of Manure
Some studies have reported that composting eliminates on
average 50–70% of some antimicrobials such as chlortetracycline,
monensin, and tylosin (Pruden et al., 2013) and reduces the
relative quantities of the blaTEM, sul3, and erm(B) genes in
manure (Le Devendec et al., 2015). However, to the best of our
knowledge, no study has shown the efficacy of this technique in
reducing amounts of colistin or mcr genes in pig manure.
The effectiveness of reducing ARGs in pig manure depends
mostly on the method manure is handled; aerobic biofiltration
of manure has been reported to reduce erm(X) more effectively
than other ARG such as erm(F), erm(B), and tet(G), while
mesophilic anaerobic digestion and lagoon storage reduced none
of these AR genes (Chen et al., 2010). There has been much
controversy concerning the efficiency of these biological manure
treatments, such as lagoons and composting, in ARG reduction
(Pruden et al., 2013), which is why more research is needed into
assessing the effectiveness of swine waste treatment processes in
the destruction of resistant bacteria and ARG in pig manure.
With the lack of regulation worldwide or international guidelines
to control the release of pig manure containing antibiotics (Wei
et al., 2011), it is difficult to reduce the spread of colistin resistance
into the environment by manure land applications.
Action in Human Medicine
Colistin is currently considered to be one of the last-resort
antibiotics used for the treatment of infections caused by
MDR-GNB in humans (Bergen et al., 2015a). Maintaining the
effectiveness of this antibiotic is a challenge for both scientists
and physicians. Nevertheless, there are several possible proposals
to optimize the use of colistin in human medicine (Figure 3).
Screen for Colistin Resistance in Patients
This step is crucial before undertaking a therapeutic intervention
using colistin, and screening should be done in both patients with
and without prior history of colistin usage (Olaitan et al., 2016b).
Hospitals should know whether or not their laboratories have the
ability and the necessary equipment to perform colistin resistance
testing and mcr-1 screening tests among admitted patients who
needed colistin as a treatment.
Prevention of Contamination by Colistin Resistant
Bacteria in Hospital
Hand hygiene plays a crucial role in achieving this goal
(Mathur, 2011). Interactive educational programs are important
to explain the steps of hand hygiene technique as well as its
rationale. Given the coproduction of mcr-1 genes and NDM
enzymes by the same colistin resistant isolates, as reported by
Du et al. (2016), we believe that the guide for the control
of healthcare-associated infections due to carbapenem-resistant
Enterobacteriaceae, published in 2012 by the USA Centers
for Disease Control and Prevention (CDC) and updated in
2015 (available from: http://www.cdc.gov/hai/organisms/cre/cr
e-toolkit/index.html), would be a very good tool to prevent
contamination by colistin resistant strains in hospitals. In
addition, the identification of a patient carrying isolates that
produce mcr-1 gene in association with carbapenemases should
be strictly considered a reason for patient isolation (Nordmann
and Poirel, 2016).
Prevention of Contamination of Humans Following
Direct Contact with Animals or Meat
Epidemiological studies have described a possible horizontal
transmission of a colistin resistant E. coli strains from pigs
(Olaitan et al., 2015) or from companion animals (Zhang, 2016)
to humans following close contact. It has been shown that
colistin-resistant E. coli was isolated from healthy individuals
without prior colistin usage (Olaitan et al., 2016b). Better hygiene,
particularly hand washing with soap or using alcohol disinfectant
after handling animals at a farm, pet shop, or slaughterhouse
is obligatory. Also, using gloves during pig or manure handling
and taking a shower at the exit of a piggery are mandatory
practices that should be enforced. As well, employees must be
particularly familiar with hand hygiene techniques and their
purpose. Considering that a high percentage of colistin resistant
E. coli is isolated from retail meat (Liu et al., 2016), consumers
should avoid any type of cross contamination between meat and
salad or other raw foods.
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Re-evaluation of Colistin Use for Selective Digestive
Decontamination
In the intensive care unit, colistin is sometimes used orally for
selective decontamination of the digestive tract (SDD), mainly
to target resistant gram-negative aerobic bacteria, along with a
short course of a parenteral broad-spectrum antimicrobial such
as cefotaxime (a third generation cephalosporin) (Silvestri et al.,
2007). This practice has been shown through meta-analysis of
randomized control trials to reduce the occurrence of respiratory
tract infections, mortality, and overall bloodstream infections
in critically ill patients (De Jonge et al., 2003; Silvestri et al.,
2007). However, it has been demonstrated that prolonged use
of colistin as part of SDD is associated with the emergence of
colistin resistance among ESBL producing K. pneumoniae isolates
(Halaby et al., 2013). The long-term effects of colistin use in
SDD was singled out as a possible source of colistin resistance
amplification, therefore the re-evaluation of this practice is
a topic of concern for intensive care units (Rawson et al.,
2016).
Evaluation and Optimization of Colistin Combination
Therapy
Several in vitro and in mouse model studies have shown
that combination of colistin with other antimicrobials such as
rifampicin and imipenem may be more effective than colistin
monotherapy in the treatment of MDR-GNB (Årdal et al., 2009;
Lagerbäck et al., 2016). A review of 15 studies involving 55 unique
patient cases found that clinical success was lower for colistin
monotherapy compared with colistin combination therapy for
treatment of infections caused by K. pneumoniae carbapenemases
(KPCs) producers (Hirsch and Tam, 2010). However, another
review reported considerable controversy regarding the clinical
efficacy of colistin combination therapy during the treatment of
MDR-GNB (Tamma et al., 2012). This interesting therapeutic
approach needs to be clinically studied in depth to assess its
effectiveness and its impact in MDR-GNB resistance occurrence.
CONCLUSION
Colistin is an antibiotic widely used in pigs for the oral control
of bacterial infections caused by E. coli and Salmonella. The
recent discovery of a plasmid-mediated mcr-1 gene encoding
for colistin resistance in Enterobacteriaceae has generated great
concern about the possible loss of effectiveness of colistin
for the treatment of MDR-GNB in humans. Because of
the large amounts of colistin used in food animals and
particularly in pigs, pig production has been pointed to as the
greatest cause of colistin resistance amplification and spread.
Consequently, experts, scientists, and government agencies have
called for a reduction of colistin use in pigs and stressed
that this antibiotic should be used only for the treatment
of diseased animals as a last-resort treatment under strict
circumstances. The mcr-1 gene has been isolated on four
continents from sources other than food animals, such as the
environment and human origins, and some E. coli isolates
carrying a plasmid-encoded mcr-1 gene were associated with
ESBL or carbapenemases enzymes. This highlights the need
for an overarching approach on the judicious use of all
antibiotics, especially those of critical importance for human
health. The One Health concept is more important than ever
to better manage colistin resistance at the human- animal-
environment interface through the use of adequate science-
based risk management policies that respect interdisciplinary
regulations. Finally, we should start thinking beyond colistin
therapy in swine and begin evaluating the effectiveness
of other alternative strategies against infections caused by
Enterobacteriaceae.
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